The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010
Open accessAbstract
The discovery of malignant cells in pleural fluid and/or parietal pleura signifies disseminated or advanced disease and a reduced life expectancy in patients with cancer.1 Median survival following diagnosis ranges from 3 to 12 months and is dependent on the stage and type of the underlying malignancy. The shortest survival time is observed in malignant effusions secondary to lung cancer and the longest in ovarian cancer, while malignant effusions due to an unknown primary have an intermediate survival time.2–6 Historically, studies showed that median survival times in effusions due to carcinoma of the breast are 5–6 months. However, more recent studies have suggested longer survival times of up to 15 months.7–10 A comparison of survival times in breast cancer effusions in published studies to 1994 calculated a median survival of 11 months.9 Currently, lung cancer is the most common metastatic tumour to the pleura in men and breast cancer in women.4 11 Together, both malignancies account for 50–65% of all malignant effusions (table 1). Lymphomas, tumours of the genitourinary tract and gastrointestinal tract account for a further 25%.2 12–14 Pleural effusions from an unknown primary are responsible for 7–15% of all malignant pleural effusions.3 13 14 Few studies have estimated the proportion of pleural effusions due to mesothelioma: studies from 1975, 1985 and 1987 identified mesothelioma in 1/271, 3/472 and 22/592 patients, respectively, but there are no more recent data to update this in light of the increasing incidence of mesothelioma.4 13 14 View this table: Table 1 Primary tumour site in patients with malignant pleural effusion Attempts have been made to predict survival based on the clinical characteristics of pleural fluid. None has shown a definite correlation: a recent systematic review of studies including 433 patients assessing the predictive value of pH concluded that low pH does not reliably predict …
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion
Dresler, C. M., Olak, J., Herndon, J. E., Richards, W. G., Scalzetti, E., Fleishman, S. B., Kernstine, K. H., Demmy, T., Jablons, D. M., Kohman, L., et al. (2005) · Chest · doi:10.1378/chest.127.3.909 · Cited by 578
Cited by
Davies, H. E., Mishra, E. K., Kahan, B. C., Wrightson, J. M., Stanton, A. E., Guhan, A., Davies, C. W. H., Grayez, J., Harrison, R., Prasad, A., et al. (2012) · JAMA · doi:10.1001/jama.2012.5535 · Cited by 657
Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline
Feller-Kopman, D. J., Reddy, C. B., DeCamp, M. M., Diekemper, R. L., Gould, M. K., Henry, T., Iyer, N. P., Lee, Y. C. G., Lewis, S. Z., Maskell, N. A., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1415st · Cited by 470
Pleurodesis: Indications and radiologic appearance
Sonoda, A., Jeudy, J., White, C. S., Kligerman, S. J., Nitta, N., Lempel, J., & Frazier, A. A. (2015) · Japanese Journal of Radiology · doi:10.1007/s11604-015-0412-7 · Cited by 21
Metadata
- Authors
- Roberts, M. E., Neville, E., Berrisford, R. G., Antunes, G., Ali, N. J., & on behalf of the BTS Pleural Disease Guideline Group
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2010-08-01
- Volume
- 65
- Issue
- Suppl 2
- Pages
- ii32-ii40
- ISSN
- 0040-6376 (ISSN-L)
- OpenAlex
- W2170829864
- Cited by
- 885
- References
- 1
- FWCI
- 24.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. https://app.cochat.ai/papers/10.1136/thx.2010.136994
- The paper
- Roberts, M. E., Neville, E., Berrisford, R. G., Antunes, G., Ali, N. J., & on behalf of the BTS Pleural Disease Guideline Group. (2010). Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax. https://doi.org/10.1136/thx.2010.136994
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.